Early and sustained improvements in motor function in rats after infusion of allogeneic umbilical cord-derived mesenchymal stem cells following spinal cord injury
- 2 November 2020
- journal article
- research article
- Published by Springer Nature in Spinal Cord
- Vol. 59 (3) , 319-327
Abstract
Study design Animal study. Objectives Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have recently been shown to hold great therapeutic potential for spinal cord injury (SCI). However, majority of the studies have been done using human cells transplanted into the rat with immunosuppression; this may not represent the outcomes that occur in humans. Herein, we present the therapeutic effect of using rat UC-MSCs (rUC-MSC) without immunosuppression in a rat model of SCI. Setting Mayo Clinic, Rochester, MN, USA. Methods Twelve female rats were randomly divided into two groups, control, and rUC-MSC group, and then subjected to a T9 moderate contusion SCI. Next, 2 × 106 rUC-MSCs or ringer-lactate solution were injected through the tail vein at 7 days post injury. Rats were assessed for 14 weeks by an open-field Basso, Beattie, and Bresnahan (BBB) motor score as well as postmortem quantification of axonal sparing/regeneration, cavity volume, and glial scar. Results Animals treated with rUC-MSCs were found to have early and sustained motor improvement (BBB score of 14.6 ± 1.9 compared to 10.1 ± 1.7 in the control group) at 14 weeks post injury (mean difference: 4.55, 95% CI: 2.04 to 7.06; p value < 0.001). Total cavity volume in the injury epicenter was significantly reduced in the rUC-MSC group; control: 33.0% ± 2.1, rUC-MSC: 25.3% ± 3.8 (mean difference: −7.7% (95% CI: −12.3 to −2.98); p value < 0.05). In addition, spinal cords from rats treated with rUC-MSCs were found to have a significantly greater number of myelinated axons, decreased astrogliosis, and reduced glial scar formation compared to control rats. Conclusions Our study indicates that intravenous injection of allogenic UC-MSCs without immunosuppression exert beneficial effects in subacute SCI and thus could be a useful therapy to improve the functional capacity among patients with SCI.Keywords
This publication has 26 references indexed in Scilit:
- Human Umbilical Cord Blood Stem Cells for Spinal Cord injury: Early Transplantation Results in Better Local AngiogenesisRegenerative Medicine, 2013
- Comparison of Mesenchymal Stem Cells Derived from Fat, Bone Marrow, Wharton’s Jelly, and Umbilical Cord Blood for Treating Spinal Cord Injuries in DogsJournal of Veterinary Medical Science, 2012
- Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcomeBrain Research, 2010
- Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injuryNeurobiology of Disease, 2009
- Effect of cyclosporin A on functional recovery in the spinal cord following contusion injuryJournal of Anatomy, 2009
- Stem cell‐based cell therapy in neurological diseases: A reviewJournal of Neuroscience Research, 2009
- Another Barrier to Regeneration in the CNS: Activated Macrophages Induce Extensive Retraction of Dystrophic Axons through Direct Physical InteractionsThe Journal of Neuroscience, 2008
- Regeneration beyond the glial scarNature Reviews Neuroscience, 2004
- Cyclosporin A Treatment Following Spinal Cord Injury to the Rat: Behavioral Effects and Stereological Assessment of Tissue SparingJournal of Neurotrauma, 2001
- A Sensitive and Reliable Locomotor Rating Scale for Open Field Testing in RatsJournal of Neurotrauma, 1995